Fludrocortisone Acetate
Phase 3Small molecule
Merck & Co.Fludrocortisone Acetate is one of 79 small molecule programs targeting Vasovagal syncope. It is currently in Phase 3.
4
Indications
13
Total Trials
4
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Fludrocortisone Acetate
Merck & Co.Phase 3
COVID-19 Vaccine
ModernaPreclinical
Aimovig
AmgenPreclinical
Singulair
AstraZenecaPreclinical
Benadryl
PParkedale
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Olokizumab
UCBPreclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Hydroxychloroquine Pill
UUniversity of Calgary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Vasovagal syncope2 trials
Interaction2 trials
COVID-191 trial
Mineralocorticoid Use in COVID-19 Patients
Completed·—·Phase 3·NCT05453214·10 enrolled
4 more indications
Moderate Hepatic Impairment1 trial
End Stage Renal Disease (ESRD)1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fludrocortisone Acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company